Development of novel anti-Kv 11.1 antibody-conjugated PEG-TiO₂ nanoparticles for targeting pancreatic ductal adenocarcinoma cells.

ABSTRACT: Titanium dioxide (TiO₂) has been widely used in many nanotechnology areas including nanomedicine, where it could be proposed for the photodynamic and sonodynamic cancer therapies. However, TiO₂ nanoformulations have been shown to be toxic for living cells. In this article, we report the development of a new delivery system, based on nontoxic TiO₂ nanoparticles, further conjugated with a monoclonal antibody against a novel and easily accessible tumor marker, e.g., the Kv 11.1 potassium channel. We synthesized, by simple solvothermal method, dicarboxylic acid-terminated PEG TiO₂ nanocrystals (PEG-TiO₂ NPs). Anti-Kv 11.1 monoclonal antibodies (Kv 11.1-Mab) were further linked to the terminal carboxylic acid groups. Proper conjugation was

SUBMITTER: Sette A 

PROVIDER: S-EPMC3857862 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature